3 documents found, page 1 of 1
Pharmacological combination of nivolumab with dendritic cell vaccines in cancer...
Calmeiro, João; Carrascal, Mylène A.; Tavares, Adriana Ramos; Ferreira, Daniel Alexandre; Gomes, Célia; Cruz, Maria Teresa; Falcão, AmílcarIn the last decade, immunotherapy led to a paradigm shift in the treatment of numerous malignancies. Alongside with monoclonal antibodies blocking programmed cell death receptor-1 (PD-1)/PD-L1 and cytotoxic T- lymphocyte antigen 4 (CTLA-4) immune checkpoints, cell-based approaches such as CAR-T cells and dendritic cell (DC) vaccines have strongly contributed to pushing forward this thrilling field. While initia...
In-Depth Analysis of the Impact of Different Serum-Free Media on the Production...
Calmeiro, João; Mendes, Luís; Duarte, Iola F.; Leitão, Catarina; Tavares, Adriana R.; Ferreira, Daniel Alexandre; Gomes, Célia; Serra, JoãoDendritic cell (DC)-based antitumor vaccines have proven to be a safe approach, but often fail to generate robust results between trials. Translation to the clinic has been hindered in part by the lack of standard operation procedures for vaccines production, namely the definition of optimal culture conditions during ex-vivo DC differentiation. Here we sought to compare the ability of three clinical grade serum...
Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventiona...
Calmeiro, João; Carrascal, Mylène A.; Tavares, Adriana Ramos; Ferreira, Daniel Alexandre; Gomes, Célia; Falcão, Amílcar; Cruz, Maria TeresaThroughout the last decades, dendritic cell (DC)-based anti-tumor vaccines have proven to be a safe therapeutic approach, although with inconsistent clinical results. The functional limitations of ex vivo monocyte-derived dendritic cells (MoDCs) commonly used in these therapies are one of the pointed explanations for their lack of robustness. Therefore, a great effort has been made to identify DC subsets with s...